For more than half a century, Lantheus Medical Imaging, Inc. has helped physicians enhance patient care with its pioneering product portfolio that illuminates the heart and other organs.  Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont and finally Bristol-Myers Squibb (BMS) Medical Imaging. During its proud history, the company discovered, developed, and launched the market-leading products Cardiolite^® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), which has become the gold standard for use in myocardial perfusion imaging, and DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for use in suboptimal echocardiograms, which is an important tool for the echocardiography community. In 2008, BMS Medical Imaging was acquired by Avista Capital Partners and formally re-launched as Lantheus Medical Imaging, operating for the first time in its proud history as an independent company.